Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS
Clinical trial NCT07498634 · COMPLETED
Trial details
- NCT number
- NCT07498634
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-21
- Primary completion
- 2025-08-01
- Enrollment
- 323
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.